Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects

NCT06233916 | Completed Phase 1 FDA Drug

• 1 other identifier: D1553-108
• Study Type: interventional
• Target: 8
• Locations: 1 country
• Sites: 1

Brief Summary

• To quantitatively analyze the total radioactivity (TRA) in excrement after a single oral dose of \[14C\] D-1553 in healthy subjects, and obtain radioactivity recovery and primary excretion pathways in humans;
• To obtain radioactive metabolite profiles of human plasma, urine and feces , identify major metabolites of D-1553 and determine the major metabolic pathways and elimination pathways;
• To quantitatively analyze the TRA in whole blood and plasma and obtain PK parameters of plasma TRA and investigate whole blood/plasma ratio for TRA.

Conditions

Mass Balance Study

Outcome Measures

Primary Outcomes (8)

• The radioactivity will be determined by a liquid scintillation counter. Analyze the total recovery (that is the ratio of the radioactivity in excrement samples to the radioactivity of the drug that administered ) in excrement

  Recovery and cumulative recovery of total radioactive substance in excrement (urine and feces)

  2 weeks

• Percentage of unchanged drug and its metabolites in plasma, urine and feces to the administered dose

  Exposure in plasma; percentage of unchanged drug and its metabolites in urine and feces to the administered dose; identification of major metabolites in plasma, urine and feces

  2 weeks

• whole blood/plasma ratio for TRA (total radioactivity) concentration at different time points

  whole blood/plasma ratio for TRA concentration at different time points

  2 weeks

• Tmax (time to maximum observed concentration) parameters of TRA;

  Tmax parameters of TRA in plasma

  baseline to 2 weeks

• t1/2 (terminal elimination half-life) parameters of TRA;

  t1/2 parameters of TRA in plasma

  baseline to 2 weeks

• Cmax (maximum concentration) parameters of TRA;

  Cmax parameters of TRA in plasma

  baseline to 2 weeks

• MRT (mean residence time) parameters of TRA;

  MRT parameters of TRA in plasma

  baseline to 2 weeks

• AUC (area under curve) parameters of TRA;

  AUC parameters of TRA in plasma

  baseline to 2 weeks

Secondary Outcomes (9)

• Incidence and severity of AEs based on NCI CTCAE V5.0

  baseline to 3 weeks

• Incidence and severity of SAEs based on NCI CTCAE V5.0

  baseline to 3 weeks

• Tmax parameters of D-1553 and its metabolites

  baseline to 2 weeks

• Cmax parameters of D-1553 and its metabolites

  baseline to 2 weeks

• AUC0-t parameters of D-1553 and its metabolites

  baseline to 2 weeks

Study Arms (1)

[14C] D-1553 group

OTHER

Single arm study

Drug: [14C] D-1553

Interventions

[14C] D-1553 DRUG

\[14C\] D-1553 (approximately 400 mg/80 μCi)

[14C] D-1553 group

Eligibility Criteria

• Age: 19 Years - 55 Years
• Gender Eligibility Details: Healthy Chinese adult male subjects aged 19-55 years (inclusive) at the time of signing the ICF.
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects who volunteer to participate in this clinical trial, understand the study procedures and sign the Informed Consent Form (ICF) in writing.
• Healthy Chinese adult male subjects aged 19-55 years (inclusive) at the time of signing the ICF.
• Body weight ≥ 50.0 kg, 19 kg/m2 ≤ body mass index (BMI) ≤ 26.0 kg/m2, and BMI = body weight (kg)/body height2 (m2) at screening.
• Subjects with normal test results or with abnormal but not clinically significant results as judged by the clinician for vital signs, physical examination, 12-lead ECG, chest radiograph (PA view), abdominal color Doppler ultrasound (liver, gallbladder, pancreas, spleen, and kidneys), ophthalmological examination, and laboratory tests (including hematology, blood chemistry, coagulation function, urinalysis, thyroid function, screening for infectious diseases, stool routine test + occult blood) during screening.
• Subjects who agree to abstain, are surgically sterilized, or agree to use an effective contraceptive method from the time of signing the ICF and for the duration of study participation to 180 days after administration of the study drug.

You may not qualify if:

• Subjects with any medical history of disorders of the central nervous system, cardiovascular system, blood and lymphatic system, immune system, urinary system, digestive system, respiratory system, and metabolic and skeletal system, etc., other acute or chronic diseases or mental diseases, which are abnormal and clinically significant at the discretion of the investigator.
• Subjects who are positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody, treponema pallidum antibody (TPA), or HIV antigen/antibody combination test (preliminary screening).
• Subjects who have smoked more than 5 cigarettes or 1 pipe per day (or equivalent of nicotine products) on average within 3 months prior to screening, or who are unable to stop using any tobacco products during the trial.
• Subjects with hemorrhoids with hematochezia or perianal disease with regular/ongoing hematochezia, or with severe nausea, vomiting, constipation or diarrhea within one week prior to screening; or with positive test results for fecal occult blood.
• Subjects with a history of blood or needle phobia.
• Subjects who have undergone a major surgery that affects the absorption or metabolism of the study drug within 6 months prior to the first dose.
• Subjects who have participated in clinical trials of other study drugs within 3 months before the first dose; if the half-life of that other investigational drug is long, the time period is limited to 5 half-lives of the drug.
• Subjects unwilling or unable to follow the life restrictions described in the study protocol (such as dietary restrictions, activity and contraceptive requirements, etc.).
• Subjects who have lost blood or donated blood, or received blood transfusions or used blood products within 1 month before administration.
• Subjects who are exposed to radioactive work conditions for a long time, or have significant radiation exposure (≥ 2 chest/abdominal CTs, or ≥ 3 other types of X-ray examinations) within 1 year before the first dose, or have participated in a radiopharmaceutical labeled trial.
• Subjects who are unsuitable for the study participation for other reasons at the discretion of the investigator.

Sponsors & Collaborators

• InventisBio Co., Ltd: lead

Study Sites (1)

beijing Gobroad Boren Hospital

Beijing, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 27, 2023
• First Posted: January 31, 2024
• Study Start: December 8, 2023
• Primary Completion: January 3, 2024
• Study Completion: January 10, 2024
• Last Updated: February 1, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)